Statistics for Phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

Total visits

views
Phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors 0

Total visits per month

views
January 2025 0
February 2025 0
March 2025 0
April 2025 0
May 2025 0
June 2025 0
July 2025 0